New FDA Pulse Oximetry Guidance: Strengths and Weaknesses
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
New FDA Pulse Oximetry Guidance: Strengths and Weaknesses
-
Narrated by:
-
By:
About this listen
The US Food and Drug Administration (FDA) issued new draft regulatory guidance for pulse oximeters related to skin pigment. The guidance is a step forward but it may have unintended consequences. Authors Michael Lipnick, MD, and Philip Bicker, MD, PhD, professors of anesthesia at University of California, San Francisco, discuss this and more with JAMA Executive Editor Gregory Curfman, MD.
Related Content:
- Pulse Oximetry and Skin Pigmentation—New Guidance From the FDA
- Adherence to FDA Guidance on Pulse Oximetry Testing Among Diverse Individuals, 1996-2024
- Addressing Racial and Ethnic Bias in Pulse Oximeters—A Wicked Problem
- Evaluating the Accuracy of Pulse Oximetry in Children According to Race
activate_mytile_page_redirect_t1
What listeners say about New FDA Pulse Oximetry Guidance: Strengths and Weaknesses
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.